About R. Tanny Kang

Tanny focuses his practice on advising global pharmaceutical companies, startup biotechs, and other technology companies on a variety of corporate, transactional, and commercial matters, including complex licensing and collaboration agreements, strategic alliances, and various operational agreements.

During law school, Tanny served as a Senior Editor for the University of Pennsylvania Law Review and interned in the U.S. District Court for the District of Columbia in the chambers of the Honorable Rudolph Contreras.

Recent work

• Innovation team of a leading healthcare provider on strategic technology and IP investments and transactions, including transactions involving novel SaMD, AI/ML and data analytic tools to improve healthcare delivery and outcomes.
• AbbVie on a strategic research collaboration and option to license HotSpot Therapeutics’ discovery-stage IRF5 small molecule allosteric therapy for the treatment of autoimmune diseases, including a $40 million upfront cash payment, an additional $295 million in option fees and R&D milestones, and the potential for commercial milestones and royalties.
• Sairopa on its collaboration, option and license agreement with Exelixis to produce novel oncology therapies
• Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc
• Moderna on its ten-year agreement with the State of Victoria to establish a state-of-the-art, domestic mRNA manufacturing facility at Monash University